Ambrx Biopharma, Inc. (NASDAQ: AMAM)


Engel Law PLLC is investigating whether fair value to Ambrx Biopharma, Inc. (NASDAQ: AMAM) shareholders will result from the proposed acquisition of Ambrx by Johnson & Johnson for $28.00 in cash for each Ambrx share.

The Firm’s investigation concerns:

(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

Ambrx Biopharma, Inc.

MM slash DD slash YYYY